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Rett syndrome (RTT) is a severe neurodevelopmental disorder caused, in most classic cases, by mutations in the
X-linked methyl-CpG-binding protein 2 gene (MECP2). A large degree of phenotypic variation has been observed
in patients with RTT, both those with and without MECP2 mutations. We describe a family consisting of a proband
with a phenotype that showed considerable overlap with that of RTT, her identical twin sister with autistic disorder
and mild-to-moderate intellectual disability, and a brother with profound intellectual disability and seizures. No
pathogenic MECP2 mutations were found in this family, and the Xq28 region that contains the MECP2 gene was
not shared by the affected siblings. Three other candidate regions were identiﬁed bymicrosatellitemapping, including
10.3 Mb at Xp22.31-pter between Xpter and DXS1135, 19.7 Mb at Xp22.12-p22.11 between DXS1135 and
DXS1214, and 16.4 Mb at Xq21.33 between DXS1196 and DXS1191. The ARX and CDKL5 genes, both of which
are located within the Xp22 region, were sequenced in the affected family members, and a deletion of nucleotide
183 of the coding sequence (c.183delT) was identiﬁed in CDKL5 in the affected family members. In a screen of
44 RTT cases, a single splice-site mutation, IVS13-1GrA, was identiﬁed in a girl with a severe phenotype overlapping
RTT. In the mouse brain, Cdkl5 expression overlaps—but is not identical to—that of Mecp2, and its expression
is unaffected by the loss of Mecp2. These ﬁndings conﬁrm CDKL5 as another locus associated with epilepsy and
X-linked mental retardation. These results also suggest that mutations in CDKL5 can lead to a clinical phenotype
that overlaps RTT. However, it remains to be determined whether CDKL5 mutations are more prevalent in speciﬁc
clinical subgroups of RTT or in other clinical presentations.
Introduction
Rett syndrome (RTT) is a devastating neurodevelop-
mental disorder that accounts for a signiﬁcant propor-
tion of severe mental retardation (MR) in females world-
wide (Ellaway 2001). It is caused by mutations in the
X-linked methyl-CpG-binding protein 2 (MECP2) gene
in ∼75% of cases (Hoffbuhr et al. 2002). Classic RTT
is characterized by apparently normal development from
birth until ∼6 mo of age, followed by regression—with
loss of acquired skills and speech—and development
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of stereotypic hand movements (Hagberg et al. 1985).
However, a wide degree of variability has been reported
in females with RTT, including severe cases with early-
onset seizures and no period of normal development,
relatively mild forme fruste cases with some preserved
skills, and some cases with preserved speech (Hagberg
and Rasmussen 1986; Goutie´res and Aicardi 1987; Hag-
berg and Skjeldal 1994; Zappella 1997).
For a genetic disorder, RTT has a relatively high in-
cidence of ∼1/10,000 among females, but familial re-
currence is rare (Talvik et al. 1995; Terai et al. 1995;
Leonard et al. 1997; Skjeldal et al. 1997; Gill et al.
2003). When there are recurrences within families, they
usually follow an X-linked dominant pattern of inher-
itance, with protective skewing in asymptomatic female
carriers and severe disease in affected males (Wan et al.
1999; Villard et al. 2000; Ben Zeev et al. 2002; Geer-
dink et al. 2002; Hoffbuhr et al. 2002; Gill et al. 2003).
Variation observed between females in these families
with RTT has generally been ascribed to differences in
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X-inactivation patterns (Miyamoto et al. 1997; Amir et
al. 2000; Cheadle et al. 2000; Van den Veyver and
Zoghbi 2000; Ishii et al. 2001; Webb and Latif 2001;
Hoffbuhr et al. 2002). In addition, an increased prev-
alence of skewing of X inactivation has been reported
in patients with RTT, including those with no identiﬁed
MECP2 mutation (Zoghbi et al. 1990b; Krepischi et al.
1998; Ishii et al. 2001; Weaving et al. 2003). Skewing
has frequently been reported in association with X-
linked disorders—and with X-linked MR in particular
(Puck and Willard 1998; Plenge et al. 2002)—so its
occurrence may be an indication that other X-linked
genes cause RTT in a proportion of cases.
Mutations inMECP2 cause most cases of classic RTT,
but a proportion of sporadic cases, and the majority of
familial cases, do not appear to have MECP2 mutations
(Cheadle et al. 2000; Huppke et al. 2000; Hoffbuhr et
al. 2001; Gill et al. 2003; Weaving et al. 2003), although
systematic screenings for large deletions (Laccone et al.
2004) or mutations involving the recently described
MECP2 isoform (Kriaucionis and Bird 2004; Mnatza-
kanian et al. 2004) have yet to be undertaken. This has
raised the possibility that RTT is a genetically hetero-
geneous disorder, especially among atypical RTT cases,
in which the prevalence of MECP2 mutations may be
as low as 44% (Weaving et al. 2003).
Here, we report patients from two families whose
conditions show considerable clinical overlap with RTT
and report mutations in CDKL5 in the ﬁrst family and
in one affected individual from the second family. These
results suggest that the phenotypic variability seen in
RTT is, in part, due to genetic heterogeneity and that
a clinical picture that overlaps RTT may be caused by
mutations in CDKL5.
Material and Methods
MECP2 Mutation Screening, X-Inactivation Analyses,
and X-Chromosome Exclusion and Haplotype Mapping
Studies
MECP2 screening was performed as described else-
where (Leonard et al. 2001; Weaving et al. 2003). In
addition, we performed multiplex-ligation–dependent
probe ampliﬁcation [MLPA] analysis (MRC-Holland),
in accordance with the manufacturer’s instructions. We
also performed PCR and direct sequencing, to screen
exon 1 of MECP2 for potentially pathogenic sequence
variations. Primers were designed to cover the whole of
exon 1, including 112 bp downstream of the intron 1
splice junction and 490 bp upstream of exon 1 (forward
primer: 5′-GCACTCGGTGCATCTGTGGACAGAG-3′;
reverse primer: 5′-CATCCGCCAGCCGTGTCGTCC-
GAC-3′). PCR was performed using 100 ng of genomic
DNA as a template in a 20-ml reaction with a concen-
tration of 0.166 mM of both primers, and 0.75mM of
dNTPs, 1.5 U of Platinum Taq polymerase (Invitrogen),
67 mM Tris-HCl (pH 8.3), 3.7 mM MgCl2, 0.5 M be-
taine, 16.6 mM (NH4)2SO4, and 0.05% dimethyl sulf-
oxide. PCR ampliﬁcation conditions were 94C for 7
min; followed by 35 cycles of denaturation at 95C for
60 s, annealing at 65C for 60 s, and extension at 72C
for 60 s; and a ﬁnal extension step for 5 min at 72C.
PCR products were sequenced in forward and reverse
directions and were analyzed as reported elsewhere
(Weaving et al. 2003), with the forward primer for se-
quencing being 5′-CAATTGACGGCATCGCCGCTGA-
GAC-3′ and the reverse sequencing primer being the one
used for PCR ampliﬁcation of this region.
X-chromosome inactivation status was analyzed using
DNA extracted from peripheral white blood cells or buc-
cal samples. Skewing of X inactivation was measured in
accordance with the method of Allen et al. (1992). For
family 2, which was not informative at the androgen
receptor locus, X-chromosome inactivation analysis
was performed using an FMR1 CGG-repeat PCR-based
assay, essentially as described by Carrel and Willard
(1996). Digestion conditions, primer sequences, and
PCR conditions are available on request.
Preliminary X-chromosome mapping was performed
using the ABI Prism set, version 2, panel 28 (X chro-
mosome), obtained from Applied Biosystems. This set
comprised primers for 18 ﬂuorescently labeled micro-
satellite markers dispersed at intervals of ∼10 cM over
the entire X chromosome. Further primer sequences for
amplifying microsatellites within regions identiﬁed as
potential candidates were obtained from the Genome
Database (see Genome Database Web site). Genetic dis-
tances and locations in centimorgans and megabases
were obtained from the Cedar Genetics X-chromosome
map, the Ensembl Human Genome Browser, and the
Integrated X Chromosome Database (see CedarGenetics
Map, Ensembl Human Genome Browser, and Integrated
X Chromosome Database Web sites). PCR conditions
were optimized for individual primers and are available
on request. Exclusion mapping was based on the hy-
pothesis of an X-linked dominant disorder shared by the
twins and the brother and inherited from the mother in
family 1. Alleles that were not shared by the affected
individuals were excluded. Alleles shared with the un-
affected sister were also considered as highly unlikely
candidate regions and were excluded. In family 2, mi-
crosatellite markers ﬂanking the CDKL5 (DXS987 and
DXS1683) and the ARX (DXS1684, DXS1177, and
DXS1108) loci were used for haplotype analysis.
Candidate-Gene Analyses
After deﬁning candidate regions through exclusion
mapping, the Aristaless-like homeobox gene (ARX) and
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the serine/threonine kinase 9 gene (STK9)—also known
as “cyclin-dependent kinase–like 5” (CDKL5 [MIM
300203])—were chosen as candidates for screening.
ARX screening was performed by sequencing of the cod-
ing region by use of the method of Strømme et al.
(2002b). CDKL5was screened by sequencing of the cod-
ing region by use of the method of Kalscheuer et al.
(2003).
cDNA Analysis of the IVS13-1GrA Mutation
To amplify across CDKL5 exons 12–15, two primers
were designed: E12F, 5′-AGAGCCAACAGCCTGCAA-
CTC-3′; and E15R, 5′-CATGGATCGAATGCTGGTT-
GTC-3′ (Tmp 60C; amplicon size 365 bp). Peripheral
blood RNA of patients II:1 and II:2 from family 2 was
isolated using standard techniques. Random hexamer-
primed cDNA was used for PCR with primers E12F and
E15R. The 365-bp product was directly sequenced and
was cloned into pGEM-T (pGEM-T Vector System I
[Promega]), in accordance with the manufacturer’s in-
structions. XL10G cells (Stratagene) were used for
transformations.
To screen clones for the 1-bp deletion (c.2047delG),
we designed a new mutant cDNA-speciﬁc primer, E14Rm
(5 ′-TGTGGGTCATGATACACTCCACCT-3 ′). The
E14Rm primer was used in conjunction with the exon
12 primer (E12F) to screen the clones. Despite the spec-
iﬁcity of the E14Rm primer for the c.2047delG allele,
the normal CDKL5 alleles (C:A mismatch) were also
ampliﬁed. However, as a result of the mismatch, the
E14Rm primer introduced a base change, compared
with the normal CDKL5 PCR product, which removes
a DdeI restriction site. After PCR, the products were
digested with DdeI, to identify clones carrying the
c.2047delG mutation. Sequencing (of normal and PCR/
DdeI-positive clones) was used to conﬁrm the results of
the DdeI restriction-enzyme digest.
Ethical approval for this study was obtained from the
Children’s Hospital at Westmead Ethics Committee, and
informed consent was obtained from subjects and from
the parents or guardians of patients.
In Situ Hybridization of Cdkl5 Expression in Mouse
Brains
The expression of Cdkl5 in the mouse brain at post-
natal week 8 was examined by whole-mount in situ
hybridization. Mouse total RNA was prepared using
Trizol, and cDNA was synthesized using Superscript 2
(Invitrogen) with oligodT primers, in accordance with
the manufacturer’s protocols. Riboprobes that hybridize
to a 467-bp sequence of exons 3–10 of the Cdkl5 gene
were prepared using the cDNA as templates (mouse
Cdkl5 sequence obtained from Mouse Genome Infor-
matics; see Mouse Genome Informatics Web site). The
forward primer was 5′-AAATGCAGACACAAGGAAA-
CAC-3′, the reverse primer was 5′-AGTAGCAGTTCT-
GGGGATCG-3′, and PCR was performed with 1 ml of
cDNA as template in a 20-ml reaction volume with a
concentration of 0.25 mM of both primers, and 0.24
mM of dNTPs, 1.35 U of AmpliTaq Gold polymerase
(Applied Biosystems), and 2.0 mM Mg2. Touchdown
ampliﬁcation conditions were 94C for 12 min; followed
by touchdown with two cycles for each 2C reduction
in the annealing temperature, with denaturation at 94C
for 30 s, annealing at 65C–55C for 30 s, and extension
at 72C for 30 s; then 30 cycles with an annealing tem-
perature of 55C for 30 s and an extension temperature
of 72C for 30 s; and a ﬁnal extension step at 72C for
10 min.
Ampliﬁed products were cloned into pGEM-T (Pro-
mega) plasmids, and clones containing inserts in both
orientations were identiﬁed and sequenced. Antisense
and sense riboprobes were generated from the NotI lin-
earized vector from the T7 RNA polymerase site, by use
of the Ampliscribe RNA Polymerase Kit (Epicentre)with
Digoxigenin-11-UTP (Roche). Brain samples for in situ
hybridization were ﬁxed in 4% paraformaldehyde and
were dissected into ∼1-mm sagittal slices. Specimens
were dehydrated and stored in 100% methanol at
20C until used for in situ hybridization by established
protocols (Davidson et al. 1999) with the following
modiﬁcations: hybridization and high-stringencywashes
were performed at 65C, followed by RNase digestion,
and BM Purple AP substrate (Roche) was used for color
development. Photography was performed under an
MZFLIII (Leica) dissecting microscope by use of a Spot
digital camera and Spot software, version 3.5 (Diag-
nostic Instruments).
Mecp2 Mutant Mouse
Mecp2-deﬁcient mice were generated by replacing the
coding sequence for the methyl-binding domain with a
ﬂoxed Pgk-neo cassette. A nonfunctional splicing site
was introduced at the 5′ end of the coding sequence
downstream of the selection cassette, to prevent correct
splicing of the transcript sequence coding the transcrip-
tion repression domain, the C-terminal domain, and the
3′ UTR. A 10.8-kb region containing exon 3 and the
ﬁrst 3 kb of exon 4 was excised with BamHI from the
BAC clone B22804 containing the Mecp2 gene and was
cloned into a pBC (Stratagene) vector. AnHpaI andNotI
digest removed 2 kb of sequence containing exon 3 and
the ﬁrst ∼170 bp of exon 4 that encode the methyl-
binding domain. The ﬂoxed Pgk-neo cassette was in-
serted into the HpaI/NotI ends of the targeting vector.
The correctly targeted embryonic stem cells were used
to produce mutant mice by germline transmission on an
R1-129 background. Mating of the Mecp2 mutant mice
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with Tnap-Cre mice resulted in the recombinase-medi-
ated deletion of the ﬂoxed Pgk-neo.
MeCP2 Antibody Generation
An N-terminal peptide consisting of human MeCP2
amino acids 9–27 (REEKSEDQDLQGLKDKPLK) was
synthesized (Auspep). A homology search, conducted us-
ing the BLAST program (see National Center for Bio-
technology Information [NCBI] Web site), revealed sig-
niﬁcant identity to only the MeCP2 protein. This peptide
sequence was used to generate antisera in rabbits con-
taining rabbit polyclonal IgG, subsequently referred to
as “LR3” (Institute of Medical and Veterinary Science,
Adelaide, Australia).
Western Analysis of MeCP2 Protein Expression in the
Mouse
Whole brain, liver, and lung tissues were collected
from mice after cervical dislocation. Nuclear extracts
were prepared using established protocols (Kuramoto et
al. 2003). In brief, tissues were homogenized (Polytron
Omni 5000) in a low-salt buffer (10 mM HEPES-NaOH
buffer [pH 7.9], 10 mM KCl, 1 mM EDTA, 1 mM
EGTA, 5 mM dithiothreitol [DTT], and 0.1% Nonidet
P-40) containing protease inhibitors and were centri-
fuged (800 # g at 4C for 30 min). The pellet was
subsequently mixed with high-salt buffer (500 mM of
KCl, 50 mM Tris (pH 8.0), 1.5 mM EDTA, 1 mM DTT,
20% glycerol, and 0.1% Nonidet P-40) containing pro-
tease inhibitors and was ultracentrifuged (180,000# g
at 4C for 30 min), and the nuclear fraction in the su-
pernatant was then used for western analyses.
Twenty micrograms of total protein was applied to
each lane of a 10% SDS-polyacrylamide gel and was
separated by electrophoresis, then transferred to a ni-
trocellulose membrane (Schleicher and Schuell). Western
blotting was performed using established procedures
(Sambrook et al. 1989). In brief, the LR3 antibody was
diluted 1:1,000 in PBS-T with 5% skim-milk powder,
and the secondary horseradish peroxidase-conjugated
goat anti-rabbit antibody (Santa Cruz) was diluted 1:
2,000. Antibody binding was detected with enhanced
chemiluminescence (Amersham Life Science).
Results
Clinical Description of Family 1
The ﬁrst family in this study consisted of a proband
with a clinical phenotype that overlaps RTT (III:1) (ﬁg.
1), her identical twin sister with autistic disorder (III:2),
and an elder brother with profound intellectual disability
and seizures who died at the age of 16 years (III:3).
Monozygosity of the twins was conﬁrmed by X-chro-
mosome microsatellite mapping and by human leuko-
cyte antigen (HLA) and red-cell antigen typing. The
family also included an unaffected older sister and an
unaffected older brother. The unaffected brother (III:4)
(ﬁg. 1) was born with the remains of a dead twin at-
tached to the placenta. The mother also had two ﬁrst-
trimester miscarriages prior to the birth of III:3. The
parents were nonconsanguineous and of white descent.
The proband (III:1) (ﬁg. 1) was a female born by cae-
sarean section at 35 wk of gestation, after a normal
pregnancy. Her head circumference at birth was 34.6
cm, and her birth weight was 2,340 g; both measures
were between the 50th and 98th percentiles. There were
no problems in the neonatal period. At 9 wk of age, she
developed infantile spasms. Despite this, her general de-
velopment was normal until 10 mo of age. She sat un-
supported at 6 mo and could be pulled to stand at 12
mo of age. She learned to crawl but never walked with-
out assistance. She developed babble, but this was lost
between 10 and 15 mo, during which time she became
totally withdrawn, showing little interest in others. She
had poor eye contact, preferring to look at bright objects
or lights. At that time, she also lost her pincer grasp.
She subsequently developed hand-wringing and hand-
mouthing stereotypies as well as breathing dysfunc-
tion with hyperventilation and breath-holding episodes.
When seen at 19 years of age, she had a thoracolumbar
scoliosis corrected by surgical fusion and was wheelchair
dependent. Her head circumference was between the 2nd
and 50th percentiles, whereas her weight and height
were well below the 3rd percentile. Her hands and feet
were small (below the 3rd percentile). She had severe
MR and a mixed seizure disorder with generalized tonic
clonic, myoclonic, and absence seizures. She had severe
constipation and generalized spasticity, hyperreﬂexia,
and peripheral vasomotor disturbance. On the basis of
a recent consensus panel review, this patient would ﬁt
the criteria for atypical RTT (Hagberg et al. 2002).
III:2 (ﬁg. 1) was the identical twin sister of III:1. Her
birth weight was 1,820 g (below the 10th percentile),
and her head circumference 30.5 cm (10th percentile).
In contrast to III:1, III:2 was described as a “stroppy,”
or hard-to-please, baby. She was difﬁcult to feed and did
not like to be cuddled. She sat unsupported at the age
of 9 mo, started to walk at 17 mo, and spoke her ﬁrst
words at 18 mo. Although she was slow to learn new
words, she was able to speak in four-ﬁve–word sentences
at 4 years. At 5 years of age, her speech was clearly
abnormal, with echolalia, lack of spontaneity, and an
insistence on sameness in replying to others. She avoided
eye gaze and interaction with peers. She has never had
seizures and has no other recognizable features of RTT.
She received a diagnosis of autism at the age of 5 years.
When seen at 19 years of age, she was very active and
demanding and had reasonable verbal skills but mild
MR (IQ assessed at ∼70). Her weight was between the
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Figure 1 Pedigree of family 1, showing results of microsatellite-exclusion mapping. Haplotypes were derived using Cyrillic v2 software
(Cyrillic Software) and are shown as differently shaded bars. The black bars represent grandpaternal alleles, the gray bars represent grandmaternal
alleles, and the striped bars represent paternal alleles. Candidate regions are indicated by boxes. X-inactivation patterns are shown as ratios
below the haplotypes. Microsatellites used in this study and their chromosomal band and map positions are given at the far left of the pedigree.
Map distances were derived from the Cedar Genetics Map of the X Chromosome, the Ensembl Human Genome Browser, and the Integrated
X Chromosome Database. The approximate positions of each of the candidate genes screened in this family are also indicated.
10th and 25th percentiles, her height was between the
3rd and 10th percentiles, and her head circumference
was between the 50th and 98th percentiles.
III:3 (ﬁg. 1) had a mixed seizure disorder of the “Len-
nox-Gastaut” type, profound intellectual impairment,
severe global developmental delay, spastic quadriparesis,
cortical blindness, and a marked kyphoscoliosis. He was
born at term after a normal pregnancy, with a birth
weight and head circumference in the 50th percentile.
He developed infantile spasms in the neonatal period,
with a sudden increase in their frequency and severity
at 9 wk of age. An electroencephalogram performed at
12 mo of age showed “hypsarrhythmia.” His develop-
ment was reported by his parents to be normal for the
ﬁrst 4 mo of life, but, between 4 and 6 mo, he developed
poor head control and adopted a ﬁsting posture of
both hands. By 1 year of age, he had severe psycho-
motor retardation, with no evidence of visual or social
responses, although auditory responses were present. At
2 years of age, he showed further developmental re-
gression, with a poor state of consciousness and frequent
seizures. His seizures remained very difﬁcult to control,
despite numerous anticonvulsants, a trial of adrenocrti-
cotropic hormone, and a ketogenic diet. At 14 years of
age, he was unresponsive and had frequent myoclonic
jerks, roving eye movements, marked kyphoscoliosis
and joint contractures, cortical blindness, and recurrent
bouts of pneumonia due to gastroesophageal reﬂux. He
had marked constipation. He was not dysmorphic, his
head circumference was in the 2nd percentile, and his
weight was below the 3rd percentile. He had no organ-
omegaly and was markedly hypertonic and hyperre-
ﬂexic. Extensive investigations failed to establish a cause
of his problems. These included a cerebral CT scan, ly-
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Figure 2 IVS13-1GrA mutation of CDKL5 in family 2. Chromatograms of the CDKL5 sequence that is mutated in family 2 are shown.
A G-to-A transversion involving the intron 13 splice-acceptor site was identiﬁed in blood DNA from the subject with an atypical RTT–like
phenotype (II:1) but not in her half sister (II:2) with classical RTT or either of her parents.
sosomal enzymes, karyotype, urinary amino- and or-
ganic-acid analyses, and urinary succinylpurines. Plasma
electrolytes, copper, acid-base status, urea, calcium,
magnesium, uric acid, blood glucose, creatinine, and
very-long-chain fatty acids were also normal. His plasma
lactate was mildly elevated, but the cerebrospinal ﬂuid
(CSF) lactate was normal. CSF neurotransmitters, glu-
cose, and protein and viral studies for herpes simplex,
measles, and varicella were normal. He had a normal
male karyotype, 46XY. Results of a skin biopsy showed
no evidence of a storage disorder or neuroaxonal dys-
trophy. He did not have the common mtDNA mutations
for mitochondrial encephalopathy, lactic acidosis, and
stroke-like episodes; myoclonic epilepsy ragged red ﬁ-
bers; Leigh syndrome; or neurogenic ataxia retinitis pig-
mentosa in a peripheral blood sample. Rectal-biopsy
electron microscopy was normal. This boy died of re-
spiratory failure at the age of 16 years, secondary to
aspiration pneumonia. In retrospect, his parents report
episodes of hyperventilation that were unrelated to feeds
and/or aspiration.
Clinical Description of Family 2
This family has been reported elsewhere (family 9 in
Gill et al. 2003). The proband (II:1) (ﬁg. 2) was born
at term after a normal pregnancy. Her birth weight was
in the 50th percentile. She smiled at 6 wk but shortly
afterward developed severe infantile spasms. Calciﬁca-
tion on her brain CT scan was suggestive of intrauterine
cytomegalovirus infection, but viral serology did not
support this diagnosis. She developed intractable sei-
zures (generalized tonic clonic, myoclonic, and absence
seizures) during childhood, which worsened during ad-
olescence and improved somewhat in adulthood, with
daily brief myoclonic seizures. Developmentally, she
made very slow progress up to 5 years of age, gaining
ﬁne and gross motor skills to a basic level but then be-
coming clumsy and losing these skills. She was a hy-
potonic child, who sat unsupported at 17 mo and stood
at 4 years of age. She spoke several single words, built
a tower of four bricks, spoon fed with help, and turned
single pages of a book. She lost these skills between 2
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years and 5 years of age. She walked independently at
7 years, with an unsteady gait, and developed a ﬁne
pincer grasp. When reviewed at age 28 years, her height,
weight, and head circumference were all below the 3rd
percentile. She had no verbal communication skills,
marked intellectual impairment, and a scoliosis that has
not required surgery. Hand stereotypies predominated
on the left side, although, in the past, these weremidline.
She hyperventilated when upset and had peripheral au-
tonomic disturbance. She had a disturbed sleep pattern
and laughed spontaneously at night. She was not dys-
morphic but was hirsute. She had dystonia with normal
reﬂexes and had small feet (below the 3rd percentile).
She was considered to have atypical RTT because of
her very poor early progress, early onset of severe
epilepsy, late and slight regression, and little, if any,
breathing abnormality or stereotypy (A. M. Kerr, per-
sonal communication).
II:2 (ﬁg. 2) was the younger half sister of the proband,
related through the mother. She was born at term after
a normal pregnancy. Her birth weight was between the
50th and 75th percentiles, and her head circumference
was in the 9th percentile. There were early maternal
concerns regarding placidity, hypotonia, and a slightly
vacant look. Her head circumference fell below the 3rd
percentile over the ﬁrst 2 years. She achieved skills to a
basic level: babbling at 9 mo, sitting with a rounded
back at 19 mo, and standing at 4 years, and she was
able to stack four bricks and unscrew lids prior to re-
gression. She regressed between 3 years and 5 years of
age, losing her hand skills and stagnating in her motor
abilities. She developed typical hand stereotypies, as well
as hyperventilation and breath-holding episodes. She
made subsequent slow progress, walking independently
at 7 years with an unsteady gait and developing a palmar
grasp. When seen at 13 years of age, she was a happy
child, keen to interact socially. She could babble “mu-
mum” and “dada” and understood several basic com-
mands, but her verbal skills were not considered sufﬁ-
cient for a diagnosis of preserved speech variant. She
had a moderate scoliosis and suffered from sleep dis-
turbance, labile mood, peripheral vasomotor distur-
bance, and mild constipation. She has never had seizures.
She had an Angelman-like facial appearance (however,
methylation and uniparental disomy studies for Angel-
man syndrome were negative [results not shown]). Her
head circumference and weight were both below the 3rd
percentile. She had marked ligamentous laxity and no
joint contractures. She had short fourth metatarsals and
small feet (below the 3rd percentile). The clinical diag-
nosis of classical RTT in this patient was independently
conﬁrmed by Dr. A. M. Kerr of the Department of Psy-
chological Medicine, University of Glasgow, Scotland
(personal communication).
MECP2 Mutation Screening
The entire coding region of the MECP2 gene (includ-
ing exon 1) was sequenced in the twins from family 1
and their affected brother. A c.426CrT sequence vari-
ation was identiﬁed in the twins but not in the affected
brother. This coded for a silent polymorphism (F142F),
but such changes can affect splicing enhancers in some
instances (Cartegni et al. 2002). Therefore, the PCR
product containing this nucleotide change was se-
quenced in the other family members. It was not iden-
tiﬁed in the affected brother or father but was seen in
the unaffected sister and mother. It thus seems unlikely
that this nucleotide change is pathogenic. No other
MECP2 changes, including large genomic rearrange-
ments screened by MPLA, were identiﬁed in this family
(results not shown). Similarly, sequencing of the two
affected individuals in family 2 revealed no pathogenic
sequence variations in any of the four MECP2 exons,
and MLPA analysis did not show any large rearrange-
ments involving this gene.
X-Chromosome Exclusion and Haplotype Mapping
Microsatellite mapping was performed on family 1,
to conﬁrm that the twins were identical and to determine
whether the Xq28 region containing the MECP2 gene
was shared among the affected siblings. Results of the
microsatellite mapping are shown in the family tree in
ﬁgure 1. The microsatellite mapping was compatible
with the twins being identical. The Xq28 region was not
shared with their affected brother but was shared be-
tween the twins and their unaffected sister. MECP2 was
thus excluded as a disease candidate gene in this family,
but the inheritance pattern and phenotypic variation still
suggested that this was an X-linked dominant condition.
Three potential candidate regions were identiﬁed
through exclusion mapping (ﬁg. 1). The ﬁrst was 10.3
Mb at Xp22.31-pter between Xpter and DXS1135, the
second was 19.7 Mb at Xp22.12-p22.11 between
DXS1135 and DXS1214, and the third was 16.4 Mb
at Xq21.33 between DXS1196 and DXS1191. Simonic
et al. (1997) observed an increase in the incidence of a
breakpoint at Xp22.1 in patients with RTT, which leads
us to favor this region. Further support for Xp22 as a
candidate region came from the report of a patient
with RTT and an (X;3)(p22.11;q13.31) translocation
(Zoghbi et al. 1990a). The candidate genes ARX and
CDKL5 both reside within the Xp22.12-p22.1 region.
In family 2, only microsatellite markers ﬂanking the
CDKL5 and MECP2 genes were used. These analyses
showed that, for both loci, the sisters inherited different
maternal and paternal X-chromosome haplotypes (re-
sults not shown). These results strongly suggest that their
clinical phenotypes of RTT have resulted from different
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Figure 3 c.183delT mutation of CDKL5 in family 1. A chromatogram of the CDKL5 sequence that is mutated in family 1 is shown.
Nucleotide numbers begin from the A of the translation start codon in exon 2. Individual ID numbers are derived from ﬁgure 1. A deletion of
nucleotide 183 was observed in the blood DNA of affected individuals (III:1, III:2, and III:3) but not in unaffected family members.
causes: the CDKL5 gene mutation in II:1 and an as-yet
unknown cause in II:2.
Candidate-Gene Mutation Screening in Family 1
TheARX gene was chosen as a candidate for screening
because of the pleiotropy of its mutations (Kato et al.
2004; Partington et al. 2004). However, no mutations
were detected in the coding region of this gene in
family 1.
The STK9 gene was chosen as a second candidate for
screening, because the phenotype of infantile spasms
overlapped that described elsewhere in association with
CDKL5 rearrangements (Kalscheuer et al. 2003). A de-
letion of nucleotide 183 (c.183delT) in exon 5 was iden-
tiﬁed in the affected siblings but not in any of the un-
affected members of family 1, including their mother,
for whom the mutation was screened in DNA extracted
from blood and buccal cells (ﬁg. 3). This deletion results
in a frameshift and a premature truncation of the gene
product at amino acid 75.
CDKL5 Screening of Other MECP2-Negative Subjects
with RTT
After the identiﬁcation of the c.183delT mutation in
CDKL5 in family 1, screening of the CDKL5 gene was
performed in 44 patients with RTT who were MECP2
mutation negative. These included cases ascertained
from Australia and the United Kingdom and one of the
probands from each of four familial cases reported by
Villard et al. (2000, 2001) who showed highly skewed
X inactivation. A splice-site mutation (IVS13-1GrA)
was identiﬁed in patient II:1 from family 2, who has the
early-onset–seizure RTT variant (see “Clinical Descrip-
tion of Family 2” section and ﬁg. 2). This patient had
a sister with classic RTT, but neither the sister nor the
parents carried the CDKL5 mutation (ﬁg. 2). This mu-
tation leads to the loss of a DdeI site. In unaffected
individuals, a 346-bp fragment encompassing this region
is cut into 185-bp and 135-bp fragments, whereas the
mutant allele is cut into 320-bp and 26-bp fragments
(results not shown).
Characterization of the CDKL5 IVS13-1GrA Mutation
The CDKL5 IVS13-1GrA mutation identiﬁed in II:1
(family 2) was not found in any of the other 43 MECP2-
mutation-negative patients with RTT who were inves-
tigated or in 236 control chromosomes. To explore the
pathogenicity of IVS13-1GrA further, we designed
primers that would amplify the cDNA from exons 12–
15, inclusive. A fragment of 365 bp was identiﬁed in an
RT-PCR of blood RNA from patient II:1. An apparently
normal CDKL5 cDNA sequence was obtained from se-
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Figure 4 cDNA and translated product of the CDKL5 IVS-1GrA mutation. A, Sequence chromatograms of representative cDNA clones
isolated from II:1 (family 2) blood RNA/cDNA. In 5 (16.6%) of 30 clones examined, a c.2047delG CDKL5 cDNA was observed. B, Illustration
of the creation of a novel intron 13 acceptor splice site as a result of the IVS13-1GrA mutation in CDKL5 of individual II:1 from family 2.
The protein sequence is shown below the genomic sequence.
quencing. However, after a more careful inspection of
the sequence chromatograms, a minor second sequence
signal could be detected in the background of the normal
sequence (mutation shown in ﬁg. 4A). Interestingly, the
background cDNA sequence appeared to be shifted by
only 1 bp. On the basis of this, we hypothesized that
the IVS13-1GrA mutation results in the activation of a
novel 3′ acceptor splice site only 1 bp away from the
original one (ﬁg. 4B). To test this hypothesis, peripheral
blood RNA of patient II:1 was used to amplify this re-
gion (exons 12–15) of the CDKL5 cDNA by RT-PCR.
Using cloning, mismatch PCR, restriction digest, and
sequencing (see “Material and Methods” section), we
identiﬁed 5 clones (of 30 analyzed) that carried the hy-
pothesized 1-bp CDKL5 cDNA deletion (c.2047delG).
The frequency of the c.2047delG clone (16.6%) among
the cloned exon 12–15 RT-PCR products is in agreement
with the X-inactivation studies, indicating that the chro-
mosome carrying the c.2047delG is active in only 15%
of peripheral blood cells (data not shown). Translation
of the mutant spliced product would create a premature
stop codon (M783X), truncating the protein approxi-
mately halfway through exon 16 (ﬁg. 5).
X Inactivation
Results from the AR assay suggested that the mother,
both of the twins, and their unaffected sister from family
1 had skewed X inactivation (ﬁg. 1). The twins had a
high degree of skewing (82% and 77%) in their blood
DNA, but this appeared to favor the same X chromo-
some. In the mother, the grandmaternal chromosome
was preferentially active in 79% of her lymphocytes,
whereas, in DNA from a buccal sample, it was 96%.
In family 2, X inactivation was studied using an FMR1
assay. The patient (II:1) had a skewed X-inactivation
pattern with a ratio of 85:15. With the use of the avail-
able family members, it was not possible to determine
which X chromosome (normal or with the CDKL5 mu-
tation) was preferentially inactivated. However, the anal-
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Figure 5 Schematic representation of the CDKL5 gene. CDKL5 exons are indicated by black boxes, and the last four exons of RS1, a
gene overlapping CDKL5, are indicated by white boxes. The alternative-splicing patterns are indicated below the diagram for the known
isoforms, I and II. Mutations and associated phenotypes that have been reported to date in association with CDKL5 mutations are given above
the diagram, and those described in the present study are shown in bold.
ysis of the CDKL5 cDNA from this patient suggested
that the chromosome carrying theCDKL5 IVS13-1GrA
mutation was preferentially inactivated (active in ∼15%
of peripheral blood cells).
Expression of Cdkl5 in Mouse Brains
In view of the potential link of the activity between
Cdkl5 and Mecp2, we examined the activity of Cdkl5
in the mouse brain, to ascertain whether Cdkl5 and
Mecp2 are expressed in similar brain regions. Whole-
mount in situ hybridization analysis of postnatal week-
8 mouse brain revealed regionalized expression of the
Cdkl5 gene in the olfactory bulb, the cerebral cortex,
the cerebellum, the hippocampal formation comprising
the hippocampus proper and dentate gyrus, the basal
ganglia, the thalamus, and the superior and inferior col-
liculi (ﬁg. 6A and 6B). A comparison of the expression
patterns of Cdkl5 and Mecp2 in the brain at the same
developmental age showed that there were signiﬁcant
overlaps of the activity of these two genes.
To examine the epistatic relationship of Cdkl5 and
Mecp2, we have tested whether Cdkl5 expression may
be inﬂuenced by that of Mecp2. This was accomplished
by studying Cdkl5 expression in the brain of Mecp2-
deﬁcient mice by whole-mount in situ hybridization. We
have produced, by gene targeting and genetic crosses,
Mecp2-deﬁcient mice. Real-time RT-PCR assays for the
1.8-kb and 10.2-kb mRNA transcripts of Mecp2 per-
formed on samples of the cerebellum and substantia ni-
gra of two 2-wk-old Mecp2/Y male mice revealed no
real-time RT-PCR products speciﬁc to the 10.2-kb or
1.8-kb transcripts in the mutant brains (data not shown).
In addition, western analysis showed that there was no
detectable Mecp2 protein in the brain tissues (ﬁg. 6D).
These ﬁndings indicate that the targeted mutation has
caused a loss of Mecp2 function. These mice exhibit a
phenotype similar to that seen in Mecp2 null mice pub-
lished elsewhere (Chen et al. 2001; Guy et al. 2001). In
brief, hemizygous males start developing symptoms by
4 wk and died by 6–8 wk, with tremors, stereotypic limb
motions, motor impairments, and hypoactivity present.
Homozygous females were not generated, and hetero-
zygous females survived well into adulthood. Further
details of phenotypic analysis of the mutant mice will
be presented in separate publications. Whole-mount in
situ hybridization analysis of the brain of week-8 Mecp2
mutant mice revealed that Cdkl5 expression was not
affected by the loss of Mecp2 activity (ﬁg. 6E and 6F).
This is an important ﬁnding that strongly suggests that
Cdkl5 activity is independent of Mecp2 activity and that
CDKL5 may act either in parallel to or upstream of
MeCP2. This is consistent with the working hypothesis
that Cdkl5 kinase regulates the function of Mecp2 by
phosphorylation of the protein.
Discussion
After exclusion mapping studies in family 1, we searched
for genes in the Xp22 region that might be disease can-
didates. Both the ARX and CDKL5 genes lie within this
Xp22 region. ARX was chosen as a candidate for screen-
ing for several reasons. Mutations in ARX have been
found in patients with epilepsy, dystonia, spastic para-
plegia, autistic behavior, and MR (Bienvenu et al. 2002;
Frints et al. 2002; Strømme et al. 2002a, 2002b; Turner
et al. 2002), some characteristics of which are exhibited
by the affected siblings in family 1. However, no mu-
tations were identiﬁed in ARX in this family.
CDKL5 was initially identiﬁed as a serine/threonine
kinase gene from sequence similarity searches (Montini
et al. 1998), but little is known about its function. Chro-
mosome translocations interrupting the gene have been
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Figure 6 Expression of CDKL5 in the mouse brain. A and B, Expression of Stk9 in the brain of wild-type postnatal week-8 mouse (A,
antisense riboprobes; B, sense riboprobes). C, Expression of Mecp2 in the brain of wild-type postnatal week-8 mouse. D, Western-blot analysis
showing the absence of the 75-kDa Mecp2 protein in the brain of the Mecp2 mutant male mouse, conﬁrming that a null mutation has been
generated by deleting the sequence coding the transcription-repression domain and the C-terminal of the protein (G. J. Pelka, C. Watson, T.
Radziewic, M. Hayward, and P. P. L. Tam, unpublished data). E and F, Expression of Stk9/Cdkl5 in the brain of postnatal week-8 Mecp2/Y
mutant male mouse (E, antisense riboprobes; F, sense riboprobes). In situ hybridization was performed on parasagittal slices of the mouse brain.
Abbreviations for brain regions: bg p basal ganglia; cb p cerebellum; cc p cerebral cortex; cp p caudate-putamen; hf p hippocampal
formation; ic p inferior colliculi; ob p olfactory bulb; sc p superior colliculi; thp thalamus.
identiﬁed in two patients with severe X-linked infantile
spasms and MR (Kalscheuer et al. 2003), and a C-ter-
minal deletion has also been described in a patient with
epilepsy and retinoschisis (Huopaniemi et al. 2000).
This led Kalscheuer et al. (2003) to propose CDKL5 as
the second locus for X-linked infantile spasms (ISSX)
syndrome, features of which were present in both fam-
ilies 1 and 2 in the present study. In family 1, a single
base-pair deletion was identiﬁed in the affected indi-
viduals, at nucleotide 183 of the coding sequence
(c.183delT) (ﬁg. 3). This mutation was not observed in
unaffected family members. The c.183delT mutation
leads to a frameshift and early truncation of the protein
at amino acid 75. Combined, these ﬁndings suggest that
this is a pathogenic mutation causing a number of clin-
ical phenotypes in this family, including early-onset
seizures and a clinical phenotype that overlaps RTT,
autistic disorder with mild-to-moderate intellectual
disability, and the phenotype in the affected male with
profound intellectual disability and seizures. The ﬁnding
that the mother does not carry the mutation was not
entirely surprising, since she herself was clinically un-
affected. Since mutation screening was performed on
blood and buccal DNA, it is likely that she is a gonadal
mosaic, carrying the mutation in her germ cells.
After identiﬁcation of the CDKL5 mutation in family
1, CDKL5 sequencing was performed on a cohort of
44 other patients with RTT and no identiﬁed pathogenic
MECP2 mutation, including one proband from each of
the four familial cases reported by Villard and col-
leagues (2001). A splice-site mutation was observed in
intron 13 (IVS13-1GrA) in a single patient with a phe-
notype characterized by the early onset of seizures and
features that overlap RTT (ﬁg. 2). This patient had a
half sister with classic RTT, but neither the sister nor
their parents appeared to carry the CDKL5 mutation.
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This phenomenon is not without precedent, since the
presence of a MECP2 mutation in one but not all af-
fected members of a family unit (who may each show
variable clinical features) has been reported elsewhere
(Gill et al. 2003). Our results from haplotype analysis
of CDKL5 and MECP2 loci in the family further sup-
port the hypothesis of different causes of the RTT phe-
notype in the half sisters.
The IVS13-1GrA mutation changes the canonical 3′
acceptor splice site of intron 13 from AG to AA. Such
a 3′ acceptor splice site has not been detected in eukar-
yotic genomes (Burset et al. 2000). It would, therefore,
be highly unlikely for it to be recognized by the splicing
machinery and thus be likely to cause abnormal splicing.
We demonstrated that the consequence of the IVS13-
1GrA change is an activation of a cryptic splice site
(81.34% consensus strength) just 1 bp downstream of
the original site (96% consensus strength) (Shapiro and
Senapathy 1987). We also showed that the IVS13-
1GrA nucleotide change leads to the production of
CDKL5 mRNA with a deletion of the G at position
2047 (c.2047delG; see ﬁg. 4). This would lead to pro-
duction of a truncated form of the STK9 protein and
is the most likely cause of the clinical presentation of
early-onset seizures and the phenotype that overlaps
RTT observed in family 2 (patient II:1).
It is interesting to note that the seizures seen in the
affected individuals reported in this study and those
mentioned in other published reports of CDKL5 gene
defects (Huopaniemi et al. 2000; Kalscheuer et al. 2003)
were early in their onset and were generally difﬁcult to
control with anticonvulsant therapies. Early-onset sei-
zures, usually more severe, have been described else-
where in patients with RTT, and these seizures may
sometimes precede the appearance of the more recog-
nizable RTT features (Steffenburg et al. 2001). Steffen-
burg et al. (2001) found an onset of seizures before a
patient’s ﬁrst birthday in 7 (18%) of 53 cases in their
series, although none were actually classiﬁed as infantile
spasms. In our Australian cohort with RTT (excluding
family 1 in the present study), 18 (7%) of 258 patients
with veriﬁed RTT had seizures in the 1st year of life,
and an MECP2 mutation was found in only 3 of 12
individuals in whom mutation screening had been per-
formed (H.L., unpublished data).
The twins from family 1 were conﬁrmed as identical
by microsatellite mapping of the X chromosome and
HLA typing but were discordant for their phenotype.
Since the twins are genetically identical, their pheno-
typic differences may only be attributable to epigenetic
or environmental differences. Although rare, discor-
dance between identical twins for the RTT phenotype
has been described elsewhere (Migeon et al. 1995; Ishii
et al. 2001). The most likely explanation for the dis-
cordance in these instances was thought to be differ-
ential skewing of X inactivation, as was observed by
Hoffbuhr et al. (2001), although the development of a
mutation in one but not the other postzygotic embryo
remains an untested possibility in these studies predat-
ing the identiﬁcation of MECP2 as the major causative
gene in RTT. However, both of the twins in family 1
had similar levels of skewing of the X chromosome (18:
82 and 23:77), and this appeared to favor the same
chromosome. As such, skewing of X inactivation does
not explain their phenotypic differences, unless some
discordance between the brain, as the primarily affected
tissue, and blood is speculated. Such differences in X-
inactivation patterns between different tissues have been
described elsewhere (Tan et al. 1993; Gale et al. 1994).
Moreover, variability in X inactivation across different
brain regions in individual heterozygousMecp2308/X mu-
tant mice has been reported (Young and Zoghbi 2004),
and this, too, could contribute to differences in the se-
verity of the clinical phenotype.
It should be noted that another group has recently
identiﬁed CDKL5 missense mutations in two patients
with diagnoses of RTT. These patients had early-onset
seizures and severe psychomotor retardation—charac-
teristics of the early-onset–seizure RTT variant—as well
as a number of other typical clinical features associated
with RTT, but they did not have the very noticeable
intense eye gaze that is characteristic of patients with
classical RTT (Tao et al. 2004 [in this issue]). Patients
with atypical RTT, including those with the early-onset–
seizure variant, are less likely to haveMECP2mutations
(Hammer et al. 2002) and so should be considered as
strong candidates for CDKL5-mutation screening.
STK9 is a putative serine/threonine kinase of un-
known function (Montini et al. 1998; Brunner et al.
1999). The mechanism by which mutations in CDKL5
produce phenotypes overlapping those seen in patients
with MECP2 mutations is, therefore, a puzzle, although
the most likely hypothesis is that they operate in the
same developmental pathway. Little work has been
done on CDKL5, but sequence comparisons have in-
dicated that its protein product is most closely related
to p56 KKIAMRE (the protein encoded by CDKL2)
and p42 KKIALRE (the protein encoded by CDKL1),
which share homology with the mitogen-activated pro-
tein (MAP) kinase family of cyclin-dependent protein
kinases (Montini et al. 1998).
It has recently been reported that phosphorylation of
MeCP2 causes it to be released from a target promoter,
resulting in transcriptional reactivation (Chen et al.
2003). It is unknown at this stage whether MeCP2 and
STK9 interact directly with each other, with MeCP2
possibly being a phosphorylation target for STK9;
whether they operate via a common developmental
pathway; or whether they might exert their effects
through unrelated mechanisms. Future work to identify
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the functional role of STK9, its relation to MeCP2, and
the mechanisms regulating both will be essential in un-
derstanding the biological processes involved in the eti-
ology of RTT and of related clinical phenotypes. Dis-
section of this developmental pathway may also identify
further RTT candidate genes and potential targets for
therapy.
Together, our results suggest that CDKL5 mutations
can give rise to a phenotype that strongly resembles
RTT. However, given the variant phenotypes seen in
family 1 and in the three other reported cases with
CDKL5mutations (Huopaniemi et al. 2000; Kalscheuer
et al. 2003), screening of a larger cohort of patients
with atypical RTT—particularly those with early-onset
seizures—and individuals with overlapping phenotypes,
including severe intellectual disability with autistic fea-
tures, may lead to the identiﬁcation of furthermutations
in this gene and may clarify the contribution of CDKL5
to the pathogenesis of RTT and related disorders.
In summary, we have identiﬁed another gene that may
cause a phenotype that shows considerable overlap with
RTT. Mutations in CDKL5 may also be associated with
the clinical phenotype of autistic spectrum disorder
with MR and complex seizure disorders in females and
the phenotype of severe neonatal-onset neurological
abnormalities in males. It remains to be determined
whether CDKL5 mutations may account for a large
proportion of cases showing signiﬁcant overlap with
RTT and in which no pathogenic MECP2 mutations
have been found. There is a need for a large-scale mul-
ticenter collaborative study using, when feasible, cases
sourced on a population basis, to investigate the role of
CDKL5, and possibly other genes from the same path-
way, in the pathogenesis of RTT and related disorders.
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